Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1 beta and interleukin-6 concentrations in patients with major depressive disorder

被引:88
|
作者
Jazayeri, Shima [2 ]
Keshavarz, Seyed A. [2 ]
Tehrani-Doost, Mehdi [1 ]
Djalali, Mahmood [2 ]
Hosseini, Mostafa [3 ]
Amini, Homayoun [1 ]
Chamari, Maryam [2 ]
Djazayery, Abolghassem [2 ]
机构
[1] Univ Tehran Med Sci, Sch Med, Dept Psychiat, Roozbeh Hosp, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Dept Biochem & Nutr, Tehran, Iran
[3] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran
关键词
Omega-3 fatty acid; Fluoxetine; Depression; Cortisol; HPA axis; Cytokine; HPA AXIS; FISH-OIL; CYTOKINES; STRESS; SYSTEM; OMEGA-3-FATTY-ACIDS; PATHOPHYSIOLOGY; CITALOPRAM; SECRETION; THERAPY;
D O I
10.1016/j.psychres.2009.04.013
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Treatment studies have suggested that omega-3 fatty acids (omega-3 FAs) as monotherapy or adjunctive treatment have therapeutic effects in depression. The authors recently reported a study in which fluoxetine and eicosapentaenoic acid (EPA), which is an omega-3 fatty acid, appeared to be equally effective in controlling depressive symptoms and their combination was superior to either of them alone. Regulation of hypothalamus-pituitary-adrenal (HPA) axis activity and reduction of inflammatory cytokines are among several biological mechanisms which potentially explain the impact of omega-3 FAs on depression. In the present study, plasma cortisol and serum interleukin-1beta (IL-1 beta) and interleukin-6 (Il-6) were measured in patients with a diagnosis of major depressive disorder (MDD) participating in aforementioned trial to determine the effects of 8 weeks of treatment of depression with 1000 mg EPA alone or in combination with 20 mg fluoxetine on HPA axis activity and inflammatory cytokine production and compare the changes in these variables with those of treating with 20 mg fluoxetine alone. Forty-two patients were included in analysis. Two-way repeated measures analysis of variance (ANOVA) showed that plasma cortisol decreased significantly after 8 weeks of intervention without significant difference among the groups. There was no interaction between group and response to treatment over time in the cortisol response based on three-way ANOVA. Serum concentrations of IL-1 beta and IL-6 did not change significantly after intervention. In conclusion, EPA alone or in combination with fluoxetine, as well as fluoxetine alone decreased serum cortisol after 8 weeks of treatment in patients with major depression disorder (MDD) without any significant effect of response to treatment. Serum IL-1 beta and IL-6 did not change significantly after intervention. These findings suggest that EPA may exert its therapeutic effects through reduction of cortisol. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:112 / 115
页数:4
相关论文
共 50 条
  • [1] Cortisol, interleukin-1 beta and interleukin-6 levels in serum of RPP patients.
    Hasse, CH
    Ergezinger, R
    Faulhaber, S
    Mengel, R
    FloresdeJacoby, L
    [J]. JOURNAL OF DENTAL RESEARCH, 1996, 75 (05) : 1224 - 1224
  • [2] Plasma interleukin-6 as a biomarker in the treatment of major depressive disorder
    Halaris, A.
    Meresh, E.
    Fareed, J.
    Hoppensteadt, D.
    Sinacore, J.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 179 - 179
  • [3] Interactions between stress, interleukin-1β, interleukin-6 and cortisol in periodontally diseased patients
    Mengel, R
    Bacher, M
    Flores-de-Jacoby, L
    [J]. JOURNAL OF CLINICAL PERIODONTOLOGY, 2002, 29 (11) : 1012 - 1022
  • [4] High concentrations of serum interleukin-6 and interleukin-8 in patients with bipolar disorder
    Lu, Yun-Rong
    Rao, Ying-Bo
    Mou, Yu-Jian
    Chen, Yan
    Lou, Han-Fen
    Zhang, Yu
    Zhang, Dan-Xuan
    Xie, Hai-Yan
    Hu, Li-Wei
    Fang, Ping
    [J]. MEDICINE, 2019, 98 (07)
  • [5] Influence of fluvoxamine on plasma interleukin-6 and on clinical improvement in Japanese major depressive disorder patients
    Yoshimura, R.
    Katsuki, A.
    Atske, K.
    Hori, H.
    Igata, R.
    Konishi, Y.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1035 - S1035
  • [6] Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures
    Uludag, Irem Fatma
    Bilgin, Sule
    Zorlu, Yasar
    Tuna, Gamze
    Kirkali, Guldal
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2013, 22 (06): : 457 - 461
  • [7] Interleukin-1β, interleukin-6 and cortisol in the blood serum of periodontal patients and the influence of indirect stress and tobacco consumption.
    Mengel, R
    Ergezzinger, R
    Hasse, C
    Flores-De-Jacoby, L
    [J]. JOURNAL OF DENTAL RESEARCH, 1998, 77 : 982 - 982
  • [8] INCREASED INTERLEUKIN-1 AND INTERLEUKIN-6 SERUM CONCENTRATIONS IN SEVERE PRIMARY PULMONARY-HYPERTENSION
    HUMBERT, M
    MONTI, G
    BRENOT, F
    SITBON, O
    PORTIER, A
    GRANGEOTKEROS, L
    DUROUX, P
    GALANAUD, P
    SIMONNEAU, G
    EMILIE, D
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (05) : 1628 - 1631
  • [9] Effects of cortisol on the expression of interleukin-6 and interleukin-1β in human osteoblast-like cells
    Swolin-Eide, D
    Ohlsson, C
    [J]. JOURNAL OF ENDOCRINOLOGY, 1998, 156 (01) : 107 - 114
  • [10] Effects of Combination Therapy of Dexamethasone and Fluoxetine on Levels of Interleukin-1β and Interleukin-6 in a Rat Model of Asthma with Depressive-like Behaviors
    Li, Chengde
    Mao, Shumei
    Wang, Yuliang
    Sun, Hongwei
    [J]. HEALTHMED, 2012, 6 (06): : 1998 - 2003